Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXRNASDAQ:MENASDAQ:PHIONASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.87-4.9%$0.85$0.65▼$26.25$9M0.87635,155 shs621,524 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.38 million shs29.28 million shsPHIOPhio Pharmaceuticals$2.27-8.1%$2.03$0.97▼$9.79$10.89M0.842.43 million shs258,608 shsSPRCSciSparc$0.32-1.0%$0.30$0.20▼$1.79$3.48M0.724.14 million shs123,032 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-8.91%+7.50%+16.91%-38.67%-94.30%ME23andMe0.00%0.00%0.00%-74.06%-93.96%PHIOPhio Pharmaceuticals-3.14%+0.41%+30.00%+91.47%-61.78%SPRCSciSparc-1.85%+2.01%-4.31%-13.49%-64.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXRCitius Pharmaceuticals2.3859 of 5 stars3.42.00.00.02.50.81.3ME23andMeN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.7541 of 5 stars3.55.00.00.02.72.51.3SPRCSciSparc0.9935 of 5 stars0.05.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.80Moderate Buy$54.506,131.42% UpsideME23andMe 1.00SellN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00516.74% UpsideSPRCSciSparc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPRC, CTXR, PHIO, and ME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$8.02 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21PHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ASPRCSciSparc$1.31M2.66N/AN/A$13.57 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$39.14MN/A0.000.70N/AN/A-51.69%-37.60%8/11/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/APHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.60N/AN/A-134.57%-108.39%8/13/2025 (Estimated)SPRCSciSparc-$5.12MN/A0.00∞N/AN/AN/AN/AN/ALatest SPRC, CTXR, PHIO, and ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.410.17ME23andMeN/A1.050.91PHIOPhio PharmaceuticalsN/A6.386.38SPRCSciSparcN/A1.861.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%ME23andMe36.10%PHIOPhio Pharmaceuticals57.31%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals10.70%ME23andMe26.32%PHIOPhio Pharmaceuticals0.59%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2010.29 million7.55 millionOptionableME23andMe77026.83 million19.77 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million6.85 millionNot OptionableSPRCSciSparc410.83 million10.20 millionNot OptionableSPRC, CTXR, PHIO, and ME HeadlinesRecent News About These CompaniesSciSparc secures Japanese patent for pain relief comboMay 28, 2025 | investing.comSciSparc Unveils Japanese Patent for Novel Pain Relief CombinationMay 27, 2025 | tipranks.comSciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEAMay 27, 2025 | quiverquant.comSciSparc Announces Publication of Japanese Patent ApplicationMay 27, 2025 | globenewswire.comSciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.May 13, 2025 | nasdaq.comSciSparc and Clearmind Secure European Patent for Cocaine Addiction TherapyMay 13, 2025 | tipranks.comSciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine AddictionMay 12, 2025 | uk.finance.yahoo.comSciSparc announces collaboration with Clearmind MedicineApril 26, 2025 | markets.businessinsider.comScisparc and Clearmind Push into Eating Disorder And Addiction Treatment With New PatentsApril 25, 2025 | theglobeandmail.comSciSparc and Clearmind File Patent for Eating Disorder TreatmentApril 25, 2025 | tipranks.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25, 2025 | globenewswire.comSciSparc Extends Deadline for Miza III Ventures DealApril 1, 2025 | tipranks.comSciSparc Ltd. Extends Merger Agreement with AutoMax MotorsApril 1, 2025 | tipranks.comSciSparc files to sell 61.21M ordinary shares for holdersMarch 26, 2025 | markets.businessinsider.comSciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent ApplicationMarch 11, 2025 | tipranks.comClearmind Medicine Inc.: Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South KoreaMarch 10, 2025 | finanznachrichten.deSciSparc announces publication of patent via Clearmind collaborationMarch 10, 2025 | markets.businessinsider.comSciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine AddictionMarch 10, 2025 | quiverquant.comSciSparc Ltd. Agrees to Sell MitoCareX to N2OFFMarch 3, 2025 | tipranks.comSciSparc Ltd: SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant CancersMarch 3, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingTop 5 Stock Buys for June: AI Picks That Aren’t NVIDIABy Thomas Hughes | May 29, 2025View Top 5 Stock Buys for June: AI Picks That Aren’t NVIDIAConstellation Energy and Meta Strike Nuclear Deal, Shares WhipsawBy Leo Miller | June 4, 2025View Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawSPRC, CTXR, PHIO, and ME Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.87 -0.05 (-4.93%) Closing price 04:00 PM EasternExtended Trading$0.87 0.00 (-0.53%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Phio Pharmaceuticals NASDAQ:PHIO$2.27 -0.20 (-8.10%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.00 (+0.22%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.SciSparc NASDAQ:SPRC$0.32 0.00 (-1.05%) Closing price 03:59 PM EasternExtended Trading$0.32 0.00 (-0.31%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
